In retrospect, the downmodulation of CXCR4 and CXCR5 by IL-4 might explain the lymphocytosis that was observed in an early clinical trial testing IL-4 therapy in CLL patients [160]. The gene discussed is CXCR5; the disease is B-cell chronic lymphocytic leukemia.